Skip to main content
The Guardian - Back to home
Support The Guardian
Contribute
Subscribe
Contribute
Search jobs
Sign in
My account
Comments & replies
Public profile
Account details
Emails & marketing
Membership
Contributions
Digital Pack
Sign out
Search
switch to the
US edition
switch to the
UK edition
switch to the
Australia edition
switch to the
International edition
current edition:
US edition
News
Opinion
Sport
Culture
Lifestyle
Show
More
News
US news
World news
Environment
Soccer
US politics
Business
Tech
Science
Opinion
The Guardian view
Columnists
Letters
Opinion videos
Cartoons
Sport
Soccer
NFL
Tennis
MLB
MLS
NBA
NHL
Culture
Film
Books
Music
Art & design
TV & radio
Stage
Classical
Games
Lifestyle
Fashion
Food
Recipes
Love & sex
Home & garden
Health & fitness
Family
Travel
Money
What term do you want to search?
Search with google
Make a contribution
Subscribe
US edition
switch to the
UK edition
switch to the
Australia edition
switch to the
International edition
Search jobs
Digital Archive
The Guardian app
Video
Podcasts
Pictures
Newsletters
Inside the Guardian
Guardian Weekly
Crosswords
Facebook
Twitter
Search jobs
Digital Archive
US
World
Environment
Soccer
US Politics
Business
Tech
Science
More
Cancer research
Immunotherapy: the big new hope for cancer treatment
Analysis: A combination therapy – helping the body’s own defences fight cancer cells – has shown impressive results for terminally ill melanoma patients
Sarah Boseley Health editor
Mon 1 Jun 2015 07.07 EDT
First published on Mon 1 Jun 2015 05.30 EDT
Share on Facebook
Share on Twitter
Share via Email
A human T-cell. The body’s defences usually attack viruses; immunotherapy helps the T-cells to treat cancer cells in the same way.
Photograph: Alamy
Immunotherapy is the most exciting development in cancer treatment in years, beginning to take off at a time when much cancer drug research seems to be hitting a brick wall. More and more of the orthodox chemotherapy drugs have very small effects, buying people with the advanced disease a few months or even just weeks of life, as the Guardian reported on Saturday.
But the scientists working on immunotherapy have set out in an entirely different direction, tricking the body’s own defences into fighting the enemy cancer within. For a long time, this has been an aspiration. The concept dates back to the 1970s and for decades the big pharmaceutical companies showed little interest. Other drugs looked like much more certain money-earners. But now there is real evidence that immunotherapy can sometimes halt terminal cancers in their tracks and big pharma is joining the bandwagon with a vengeance.
Cancer trial of drug combination yields 'spectacular' results
Read more
In Chicago, at the American Society for Clinical Oncology (Asco) annual meeting, where so many promising cancer drugs have been announced in the past – not always in the long term fulfilling the high hopes – experts are saying that the results of a trial involving a combination of two new immunotherapy drugs for melanoma (skin cancer) patients are spectacular.
Half the patients in the British trial, considered terminally ill and with little time left, responded to ipilimumab, a drug licensed four years ago, combined with the new and as-yet-unlicensed drug nivolumab. On its own, ipilimumab works for around a fifth of patients. The combination of the two shrank the tumours of 58% of patients. There is hope they may disappear altogether. Results from the trial of 945 patients, led by the Royal Marsden hospital in London, were published in the New England Journal of Medicine to coincide with the conference presentation.
Both ipilimumab, sold under the brand name Yervoy, and nivolumab were developed by an American biotech firm called Medarex, based in New Jersey and set up by a handful of immunologists from Dartmouth medical school. Their belief in immunotherapy for cancer has been amply rewarded – in 2009, their small company was bought by the pharma giant Bristol-Myers Squibb. The following year, Bristol-Myers Squibb announced the first major trial results of ipilimumab. Companies have been clambering over each other to get involved ever since.
Excitement over new cancer drugs is a dangerous thing. There have been melanoma drugs before that were greeted as miracle cures. These “targeted drugs”, the BRAF inhibitors, caused tumours to vanish completely. There was euphoria at cancer conferences. But within a few months, the disease came back with a vengeance and killed.
But the enthusiasm for immunotherapy may be better placed because this is a whole new way of tackling cancer. Scientists have long puzzled over the failure of the body’s own defensive immune system to attack cancer cells in the same way that it will fight a cold virus. They have discovered that cancer – just like the human immunodeficiency virus (HIV) that causes Aids – can hide from the T-cells that seek out and kill invaders. Cancer Research UK, which has been funding some of the research, says the cancer cells have developed a sort of “secret handshake” which persuades the T-cells not to attack.
In 1992, Japanese scientists discovered a molecule on the T-cells that was part of this secret handshake. They called it “programmed death 1” or PD1 and set out trying to disrupt it. The new drugs are the long-term result. They appear to work – at least for now – in advanced melanoma, which has a high death rate. Unlike other drugs, they are likely to work in a whole range of other cancers, too.
There are issues, as always. One is the likelihood of serious side effects. Dr Alan Worsley, from Cancer Research UK, said: “This research suggests that we could give a powerful one-two punch against advanced melanoma by combining immunotherapy treatments. Together these drugs could release the brakes on the immune system while blocking cancer’s ability to hide from it.
“But combining these treatments also increases the likelihood of potentially quite severe side effects. Identifying which patients are most likely to benefit will be key to bringing our best weapons to bear against the disease.”
Some patients have dropped out of the trials because of the side effects, which include feeling very sick. “Your immune system is designed normally not to attack your body’s own cells,” said Nell Barrie, of CRUK. “You have to boost the immune system beyond its normal function and you are going to sensitise the immune system. It’s very, very complex.”
The other big question will be how long the drugs will keep the cancers at bay. Most drugs for advanced cancers have delayed progression of the disease but not cured it. The immunotherapy drugs have not been used for long enough to be sure whether they will have a big impact on survival. But the big hope is that immunotherapy may be able to teach the body’s immune system to recognise and destroy cancer cells – and keep doing it so that the cancer is banished for good. And that is a truly exciting idea.
Ipilimumab was approved by Nice (the National Institute for Health and Care Excellence) for advanced skin cancer patients in December 2012 in spite of the high cost of £75,000 for a four-dose treatment course, because Bristol-Myers Squibb agreed to give the Department of Health an acceptably sized discount. Nivolumab is likely to get its license this summer, which will allow patients outside the Royal Marsden’s clinical trial to have it, as long as a similar acceptable price can be negotiated with the company.
Topics
Cancer research
Medical research
Cancer
Health
analysis
Share on Facebook
Share on Twitter
Share via Email
Share on LinkedIn
Share on Pinterest
Share on WhatsApp
Share on Messenger
Reuse this content
View all comments >
Order by
newest
oldest
recommendations
Show 25
25
50
100
All
Threads
collapsed
expanded
unthreaded
Loading comments… Trouble loading?
View more comments
<form class="component js-comment-box d-comment-box">
<div class="d-comment-box__meta">
<span class="d-comment-box__avatar-wrapper"></span>
<div class="d-comment-box__meta-text">
<span class="d-comment-box__author-label">Signed in as</span>
<span class="d-comment-box__author"></span>
<span
class="inline-reply inline-icon grey" >
<svg width="18" height="18" class="grey__svg inline-reply__svg inline-icon__svg">
<path d="M10.1 5l.9-1 4 4.5v1L11 14l-.9-1 2.5-3H4L3 9V6.5h2V8h7.6l-2.5-3z" />
</svg>
</span>
<span class="d-comment-box__reply-to-author"></span>
<span class="u-fauxlink d-comment-box__show-parent" role="button">Show comment</span>
<span class="u-fauxlink d-comment-box__hide-parent" role="button">Hide comment</span>
</div>
</div>
<div class="d-comment-box__parent-comment-wrapper">
<div class="d-comment-box__parent-comment-spout"></div>
<div class="d-comment-box__parent-comment">
<span class="d-comment-box__parent-comment-author"></span>
<div class="d-comment-box__parent-comment-body"></div>
<span class="u-fauxlink d-comment-box__hide-parent" role="button">Hide comment</span>
</div>
</div>
<div class="d-comment-box__onboarding">
<h3>Welcome <span class="d-comment-box__onboarding-author"></span>, you’re about to make your first comment!</h3>
<p>Before you post, we’d like to thank you for joining the debate - we’re glad you’ve chosen to participate and we value your opinions and experiences.</p>
<div class="d-comment-box__onboarding-username">
<p>Please choose your username under which you would like all your comments to show up. You can only set your username once.</p>
<label class="d-comment-box__onboarding-username-label" for="usernameInput">Username: </label>
<span>Must be 6-20 characters, letters and/or numbers only, no spaces.</span>
<input type="text" id="usernameInput" class="d-comment-box__onboarding-username-input" placeholder="" value=""/>
<p class="d-comment-box__onboarding-username-error-message is-hidden"></p>
</div>
<p>Please keep your posts respectful and abide by the <a target="_blank" href="/community-standards">community guidelines</a> - and if you spot a comment you think doesn’t adhere to the guidelines, please use the ‘Report’ link next to it to let us know.</p>
<p>Please preview your comment below and click ‘post’ when you’re happy with it.</p>
<div class="d-comment-box__onboarding-preview-body"></div>
<button type="submit" class="u-button-reset button button--large button--primary submit-input--behaviour d-comment-box__onboarding-submit">Post your comment</button>
<button type="button" class="u-button-reset button button--large button--primary submit-input--behaviour d-comment-box__onboarding-cancel">Cancel</button>
</div>
<div class="d-comment-box__content">
<div class="d-comment-box__messages"></div>
<div class="d-discussion__error d-comment-box__premod">
<span
class="inline-status-alert inline-icon " >
<svg width="18" height="18" viewbox="0 0 18 18" class="inline-status-alert__svg inline-icon__svg">
<circle fill="#d61d00" cx="9" cy="9" r="9" />
<path fill="#fff" d="M9.7 11.3H8.3L6.9 3.6l.7-.7h2.8l.7.8-1.4 7.6zM9 15.4c-.8 0-1.4-.6-1.4-1.4 0-.8.6-1.4 1.4-1.4s1.4.6 1.4 1.4c0 .8-.6 1.4-1.4 1.4z" />
</svg>
</span>
<span class="d-discussion__error-text">Your comments are currently being pre-moderated (<a href="/community-faqs#311" target="_blank">why?</a>)</span>
</div>
<div class="d-comment-box__community-standards">Please keep comments respectful and abide by the <a href="/community-standards">community guidelines</a>.</div>
<label for="d-comment-box" class="u-h">Enter comment</label>
<textarea name="body" class="textarea d-comment-box__body" placeholder="Join the discussion…" id="d-comment-box"></textarea>
<button type="submit" data-link-name="post comment" class="u-button-reset button button--large button--primary submit-input--behaviour d-comment-box__submit">Post your comment</button>
<span class="u-fauxlink d-comment-box__preview" role="button">Preview</span>
<span class="u-fauxlink d-comment-box__hide-preview" role="button">Hide preview</span>
<span class="u-fauxlink d-comment-box__cancel" role="button">Cancel</span>
<ul class="d-comment-box__formatting-controls">
<li class="d-comment-box__formatting-bold" title="Bold">B</li>
<li class="d-comment-box__formatting-italic" title="Italic">i</li>
<li class="d-comment-box__formatting-quote" title="Quote">&#8221;</li>
<li class="d-comment-box__formatting-link" title="Link">Link</li>
</ul>
<div class="d-comment-box__preview-wrapper">
<div class="d-comment-box__preview-spout"></div>
<div class="d-comment-box__preview-block">
<div class="d-comment-box__preview-body"></div>
</div>
</div>
</div>
</form>
Most popular
US
World
Environment
Soccer
US Politics
Business
Tech
Science
About us
Contact us
Complaints & corrections
Secure Drop
Work for us
Privacy policy
Cookie policy
Terms & conditions
Help
All topics
All writers
Digital newspaper archive
Facebook
Twitter
Advertise with us
Guardian Labs
Search jobs
Support The Guardian
Contribute
Subscribe
Back to top
© 2019 Guardian News and Media Limited or its affiliated companies. All rights reserved.
Close
try{(function(isVeryModern,document,window){if(isVeryModern){var decodeBase64=function(str){return decodeURIComponent(atob(str.replace(/-/g,"+").replace(/_/g,"/").replace(/,/g,"\x3d")))};var cookieData=function(a){var d=[],e=document.cookie.split(";");a=RegExp("^\\s*"+a+"\x3d\\s*(.*?)\\s*$");for(var b=0;b<e.length;b++){var f=e[b].match(a);f&&d.push(f[1])}if(d.length>0)return d[0];return null}("GU_U");var userData=cookieData?JSON.parse(decodeBase64(cookieData.split(".")[0])):null;if(userData){var displayName=decodeURIComponent(userData[2]);window.guardian.config.user={id:userData[0],displayName:displayName,accountCreatedDate:userData[6],emailVerified:userData[7],rawResponse:cookieData}}}})(guardian.isEnhanced&&"atob"in window,document,window)}catch(e){};try{(function(document,window){if(typeof window.getComputedStyle!=="function")return;var ad=document.createElement("div");ad.style.position="absolute";ad.style.left="0";ad.style.top="0";ad.style.height="10px";ad.style.zIndex="-1";ad.innerHTML="\x26nbsp;";ad.setAttribute("class","ad_unit");window.requestAnimationFrame(function(){document.body.appendChild(ad);window.requestAnimationFrame(function(){var adBlockers=window.guardian.adBlockers;var adStyles=window.getComputedStyle(ad);var displayProp=adStyles&&adStyles.getPropertyValue("display");var mozBindingProp=adStyles&&adStyles.getPropertyValue("-moz-binding");adBlockers.active=displayProp==="none"||mozBindingProp&&mozBindingProp.indexOf("about:")!==-1;runEachListener(adBlockers.onDetect);adBlockers.onDetect={push:function(){var toRun=Array.prototype.slice.call(arguments,0);runEachListener(toRun)}};function runEachListener(listeners){for(var i=0;i<listeners.length;i++)try{listeners[i](adBlockers.active)}catch(e){}}})})})(document,window)}catch(e){};try{(function(isVeryModern,document,window){var user=window.guardian.config.user;if(isVeryModern&&user)window.requestAnimationFrame(function(){var $profileInfoElem=document.getElementsByClassName("js-profile-info")[0];var $profileNavElem=document.getElementsByClassName("js-profile-nav")[0];if(!$profileInfoElem&&!$profileNavElem)return;$profileInfoElem.innerHTML=user.displayName;$profileNavElem.classList.add("is-signed-in");var $signInLinkElem=$profileNavElem.getElementsByTagName("a")[0];if($signInLinkElem)if(user.id)$signInLinkElem.addEventListener("click",function(e){e.preventDefault()});else $signInLinkElem.setAttribute("href",$signInLinkElem.getAttribute("href").replace("signin","public/edit/"));var $register=document.getElementsByClassName("js-profile-register");if($register.length){$register=$register[0];$register.parentElement.removeChild($register)}})})("classList"in document.documentElement,document,window)}catch(e){};try{(function(document,window){if(!window.__cmp)window.__cmp=function(){var listen=window.attachEvent||window.addEventListener;listen("message",function(event){window.__cmp.receiveMessage(event)},false);function addLocatorFrame(){if(!window.frames["__cmpLocator"])if(document.body){var frame=document.createElement("iframe");frame.style.display="none";frame.name="__cmpLocator";frame.setAttribute("aria-hidden",true);document.body.appendChild(frame)}else setTimeout(addLocatorFrame,5)}addLocatorFrame();var commandQueue=[];var cmp=function(command,parameter,callback){if(command==="ping"){if(callback)callback({gdprAppliesGlobally:!!(window.__cmp&&window.__cmp.config&&window.__cmp.config.storeConsentGlobally),cmpLoaded:false})}else commandQueue.push({command:command,parameter:parameter,callback:callback})};cmp.commandQueue=commandQueue;cmp.receiveMessage=function(event){var data=event&&event.data&&event.data.__cmpCall;if(data)commandQueue.push({callId:data.callId,command:data.command,parameter:data.parameter,event:event})};cmp.config={storeConsentGlobally:false,storePublisherData:false,logging:false,gdprApplies:false};return cmp}()})(document,window)}catch(e){};try{(function(document,window){function shouldServeLotame(){try{var geo=JSON.parse(window.localStorage.getItem("gu.geolocation")).value;if(geo==="US"||geo==="CA"||geo==="AU"||geo==="NZ")return false;return true}catch(e){}return false}if(shouldServeLotame()){var script=document.createElement("script");script.src="https://tags.crwdcntrl.net/c/12666/cc.js";document.body.appendChild(script)}})(document,window)}catch(e){};(function(window,document){function getCookieValue(name){var nameEq=name+"\x3d",cookies=document.cookie.split(";"),value=null;cookies.forEach(function(cookie){while(cookie.charAt(0)===" ")cookie=cookie.substring(1,cookie.length);if(cookie.indexOf(nameEq)===0)value=cookie.substring(nameEq.length,cookie.length)});return value}window.guardian.config.ophan.browserId=getCookieValue("bwid")})(window,document);window.curlConfig={baseUrl:'https://assets.guim.co.uk/javascripts',apiName:'require',paths:{'ophan/ng':'//j.ophan.co.uk/ophan.ng'}};window.curl=window.curlConfig;(function(){(function(l){function p(){}function v(a,b){return 0==T.call(a).indexOf("[object "+b)}function x(a){return a&&"/"==a.charAt(a.length-1)?a.substr(0,a.length-1):a}function D(a,b){var d,c,f,g;d=1;c=a;"."==c.charAt(0)&&(f=!0,c=c.replace(U,function(a,b,c,f){c&&d++;return f||""}));if(f){f=b.split("/");g=f.length-d;if(0>g)return a;f.splice(g,d);return f.concat(c||[]).join("/")}return c}function C(a){var b=a.indexOf("!");return{g:a.substr(b+1),d:0<=b&&a.substr(0,b)}}function A(){}function y(a,b){A.prototype=a||N;var d=new A;A.prototype=N;for(var c in b)d[c]=b[c];return d}function E(){function a(a,b,d){c.push([a,b,d])}function b(a,b){for(var d,f=0;d=c[f++];)(d=d[a])&&d(b)}var d,c,f;d=this;c=[];f=function(d,n){a=d?function(a){a&&a(n)}:function(a,b){b&&b(n)};f=p;b(d?0:1,n);b=p;c=s};this.m=function(b,c,f){a(b,c,f);return d};this.h=function(a){d.C=a;f(!0,a)};this.f=function(a){d.qa=a;f(!1,a)};this.w=function(a){b(2,a)}}function z(a){return a instanceof E||a instanceof h}function t(a,b,d,c){z(a)?a.m(b,d,c):b(a)}function B(a,b,d){var c;return function(){0<=--a&&b&&(c=b.apply(s,arguments));0==a&&d&&d(c);return c}}function e(){var a,b;r="";a=[].slice.call(arguments);v(a[0],"Object")&&(b=a.shift(),b=w(b));return new h(a[0],a[1],a[2],b)}function w(a,b,d){var c;r="";if(a&&(k.R(a),q=k.b(a),"preloads"in a&&(c=new h(a.preloads,s,d,I,!0),k.l(function(){I=c})),a=a.main))return new h(a,b,d)}function h(a,b,d,c,f){var g;g=k.k(q,s,[].concat(a),f);this.then=this.m=a=function(a,b){t(g,function(b){a&&a.apply(s,b)},function(a){if(b)b(a);else throw a;});return this};this.next=function(a,b,c){return new h(a,b,c,g)};this.config=w;(b||d)&&a(b,d);k.l(function(){t(f||I,function(){t(c,function(){k.r(g)},d)})})}function K(a){var b,d;b=a.id;b==s&&(J!==s?J={I:"Multiple anonymous defines encountered"}:(b=k.da())||(J=a));if(b!=s){d=u[b];b in u||(d=k.j(b,q),d=k.F(d.b,b),u[b]=d);if(!z(d))throw Error("duplicate define: "+b);d.ha=!1;k.G(d,a)}}function F(){var a=k.aa(arguments);K(a)}var r,q,G,H,m=l.document,O=m&&(m.head||m.getElementsByTagName("head")[0]),V=O&&O.getElementsByTagName("base")[0]||null,Q={},R={},L={},W="addEventListener"in l?{}:{loaded:1,complete:1},N={},T=N.toString,s,u={},M={},I=!1,J,S=/^\/|^[^:]+:\/\//,U=/(\.)(\.?)(?:$|\/([^\.\/]+.*)?)/g,X=/\/\*[\s\S]*?\*\/|\/\/.*?[\n\r]/g,Y=/require\s*\(\s*(["'])(.*?[^\\])\1\s*\)|[^\\]?(["'])/g,Z=/\s*,\s*/,P,k;k={n:function(a,b,d){var c;a=D(a,b);if("."==a.charAt(0))return a;c=C(a);a=(b=c.d)||c.g;a in d.c&&(a=d.c[a].M||a);b&&(0>b.indexOf("/")&&!(b in d.c)&&(a=x(d.P)+"/"+b),a=a+"!"+c.g);return a},k:function(a,b,d,c){function f(b,c){var d,g;d=k.n(b,n.id,a);if(!c)return d;g=C(d);if(!g.d)return d;d=u[g.d];g.g="normalize"in d?d.normalize(g.g,f,n.b)||"":f(g.g);return g.d+"!"+g.g}function g(b,d,g){var e;e=d&&function(a){d.apply(s,a)};if(v(b,"String")){if(e)throw Error("require(id, callback) not allowed");g=f(b,!0);b=u[g];if(!(g in u))throw Error("Module not resolved: "+g);return(g=z(b)&&b.a)||b}t(k.r(k.k(a,n.id,b,c)),e,g)}var n;n=new E;n.id=b||"";n.ea=c;n.H=d;n.b=a;n.A=g;g.toUrl=function(b){return k.j(f(b,!0),a).url};n.n=f;return n},F:function(a,b,d){var c,f,g;c=k.k(a,b,s,d);f=c.h;g=B(1,function(a){c.q=a;try{return k.V(c)}catch(b){c.f(b)}});c.h=function(a){t(d||I,function(){f(u[c.id]=M[c.url]=g(a))})};c.J=function(a){t(d||I,function(){c.a&&(g(a),c.w(R))})};return c},U:function(a,b,d,c){return k.k(a,d,s,c)},ca:function(a){return a.A},K:function(a){return a.a||(a.a={})},ba:function(a){var b=a.t;b||(b=a.t={id:a.id,uri:k.L(a),exports:k.K(a),config:function(){return a.b}},b.a=b.exports);return b},L:function(a){return a.url||(a.url=k.D(a.A.toUrl(a.id),a.b))},R:function(a){var b,d,c,f,g;b="curl";d="define";c=f=l;if(a&&(g=a.overwriteApi||a.oa,b=a.apiName||a.ja||b,c=a.apiContext||a.ia||c,d=a.defineName||a.la||d,f=a.defineContext||a.ka||f,G&&v(G,"Function")&&(l.curl=G),G=null,H&&v(H,"Function")&&(l.define=H),H=null,!g)){if(c[b]&&c[b]!=e)throw Error(b+" already exists");if(f[d]&&f[d]!=F)throw Error(d+" already exists");}c[b]=e;f[d]=F},b:function(a){function b(a,b){var d,c,n,e,q;for(q in a){n=a[q];v(n,"String")&&(n={path:a[q]});n.name=n.name||q;e=f;c=C(x(n.name));d=c.g;if(c=c.d)e=g[c],e||(e=g[c]=y(f),e.c=y(f.c),e.e=[]),delete a[q];c=n;var r=b,h=void 0;c.path=x(c.path||c.location||"");r&&(h=c.main||"."+"/"+"main","."==h.charAt(0)||(h="."+"/"+""+h),c.M=D(h,c.name+"/"));c.b=c.config;c.b&&(c.b=y(f,c.b));c.S=d.split("/").length;d?(e.c[d]=c,e.e.push(d)):e.o=k.Q(n.path,f)}}function d(a){var b=a.c;a.O=RegExp("^("+a.e.sort(function(a,c){return b[c].S-b[a].S}).join("|").replace(/\/|\./g,"\\$&")+")(?=\\/|$)");delete a.e}var c,f,g,n;"baseUrl"in
a&&(a.o=a.baseUrl);"main"in a&&(a.M=a.main);"preloads"in a&&(a.pa=a.preloads);"pluginPath"in a&&(a.P=a.pluginPath);if("dontAddFileExt"in a||a.i)a.i=RegExp(a.dontAddFileExt||a.i);c=q;f=y(c,a);f.c=y(c.c);g=a.plugins||{};f.plugins=y(c.plugins);f.v=y(c.v,a.v);f.u=y(c.u,a.u);f.e=[];b(a.packages,!0);b(a.paths,!1);for(n in g)a=k.n(n+"!","",f),f.plugins[a.substr(0,a.length-1)]=g[n];g=f.plugins;for(n in g)if(g[n]=y(f,g[n]),a=g[n].e)g[n].e=a.concat(f.e),d(g[n]);for(n in c.c)f.c.hasOwnProperty(n)||f.e.push(n);d(f);return f},j:function(a,b){var d,c,f,g;d=b.c;f=S.test(a)?a:a.replace(b.O,function(a){c=d[a]||{};g=c.b;return c.path||""});return{b:g||q,url:k.Q(f,b)}},Q:function(a,b){var d=b.o;return d&&!S.test(a)?x(d)+"/"+a:a},D:function(a,b){return a+((b||q).i.test(a)?"":".js")},s:function(a,b,d){var c=m.createElement("script");c.onload=c.onreadystatechange=function(d){d=d||l.event;if("load"==d.type||W[c.readyState])delete L[a.id],c.onload=c.onreadystatechange=c.onerror="",b()};c.onerror=function(){d(Error("Syntax or http error: "+a.url))};c.type=a.N||"text/javascript";c.charset="utf-8";c.async=!a.fa;c.src=a.url;L[a.id]=c;O.insertBefore(c,V);return c},W:function(a){var b=[],d;("string"==typeof a?a:a.toSource?a.toSource():a.toString()).replace(X,"").replace(Y,function(a,f,g,e){e?d=d==e?s:d:d||b.push(g);return""});return b},aa:function(a){var b,d,c,f,g,e;g=a.length;c=a[g-1];f=v(c,"Function")?c.length:-1;2==g?v(a[0],"Array")?d=a[0]:b=a[0]:3==g&&(b=a[0],d=a[1]);!d&&0<f&&(e=!0,d=["require","exports","module"].slice(0,f).concat(k.W(c)));return{id:b,q:d||[],B:0<=f?c:function(){return c},p:e}},V:function(a){var b;b=a.B.apply(a.p?a.a:s,a.q);b===s&&a.a&&(b=a.t?a.a=a.t.exports:a.a);return b},G:function(a,b){a.B=b.B;a.p=b.p;a.H=b.q;k.r(a)},r:function(a){function b(a,b,c){e[b]=a;c&&r(a,b)}function d(b,c){var d,f,g,e;d=B(1,function(a){f(a);m(a,c)});f=B(1,function(a){r(a,c)});g=k.Y(b,a);(e=z(g)&&g.a)&&f(e);t(g,d,a.f,a.a&&function(a){g.a&&(a==Q?f(g.a):a==R&&d(g.a))})}function c(){a.h(e)}var f,g,e,q,h,r,m;e=[];g=a.H;q=g.length;0==g.length&&c();r=B(q,b,function(){a.J&&a.J(e)});m=B(q,b,c);for(f=0;f<q;f++)h=g[f],h in P?(m(P[h](a),f,!0),a.a&&a.w(Q)):h?d(h,f):m(s,f,!0);return a},Z:function(a){k.L(a);k.s(a,function(){var b=J;J=s;!1!==a.ha&&(!b||b.I?a.f(Error(b&&b.I||"define() missing or duplicated: "+a.url)):k.G(a,b))},a.f);return a},Y:function(a,b){var d,c,f,g,e,h,r,m,w,l,p,s;d=b.n;c=b.ea;f=b.b||q;e=d(a);e in u?h=e:(g=C(e),m=g.g,h=g.d||m,w=k.j(h,f));if(!(e in u))if(s=k.j(m,f).b,g.d)r=h;else if(r=s.moduleLoader||s.na||s.loader||s.ma)m=h,h=r,w=k.j(r,f);h in u?l=u[h]:w.url in M?l=u[h]=M[w.url]:(l=k.F(s,h,c),l.url=k.D(w.url,w.b),u[h]=M[w.url]=l,k.Z(l));h==r&&(g.d&&f.plugins[g.d]&&(s=f.plugins[g.d]),p=new E,t(l,function(a){var b,f,g;g=a.dynamic;m="normalize"in a?a.normalize(m,d,l.b)||"":d(m);f=r+"!"+m;b=u[f];if(!(f in u)){b=k.U(s,f,m,c);g||(u[f]=b);var e=function(a){g||(u[f]=a);b.h(a)};e.resolve=e;e.reject=e.error=b.f;a.load(m,b.A,e,s)}p!=b&&t(b,p.h,p.f,p.w)},p.f));return p||l},da:function(){var a;if(!v(l.opera,"Opera"))for(var b in L)if("interactive"==L[b].readyState){a=b;break}return a},$:function(a){var b=0,d,c;for(d=m&&(m.scripts||m.getElementsByTagName("script"));d&&(c=d[b++]);)if(a(c))return c},X:function(){var a,b="";(a=k.$(function(a){(a=a.getAttribute("data-curl-run"))&&(b=a);return a}))&&a.setAttribute("data-curl-run","");return b},T:function(){function a(){k.s({url:c.shift()},b,b)}function b(){r&&(c.length?(k.l(d),a()):d("run.js script did not run."))}function d(a){throw Error(a||"Primary run.js failed. Trying fallback.");}var c=r.split(Z);c.length&&a()},l:function(a){setTimeout(a,0)}};P={require:k.ca,exports:k.K,module:k.ba};e.version="0.8.9";e.config=w;F.amd={plugins:!0,jQuery:!0,curl:"0.8.9"};q={o:"",P:"curl/plugin",i:/\?|\.js\b/,v:{},u:{},plugins:{},c:{},O:/$^/};G=l.curl;H=l.define;G&&v(G,"Object")?(l.curl=s,w(G)):k.R();(r=k.X())&&k.l(k.T);u.curl=e;u["curl/_privileged"]={core:k,cache:u,config:function(){return q},_define:K,_curl:e,Promise:E}})(this.window||"undefined"!=typeof global&&global||this);(function(l,p){function v(){if(!p.body)return!1;F||(F=p.createTextNode(""));try{return p.body.removeChild(p.body.appendChild(F)),F=K,!0}catch(e){return!1}}function x(){var r;r=A[p[C]]&&v();if(!z&&r){z=!0;for(clearTimeout(h);e=w.pop();)e();E&&(p[C]="complete");for(var q;q=y.shift();)q()}return r}function D(){x();z||(h=setTimeout(D,t))}var C="readyState",A={loaded:1,interactive:1,complete:1},y=[],E=p&&"string"!=typeof p[C],z=!1,t=10,B,e,w=[],h,K,F;B="addEventListener"in l?function(e,h){e.addEventListener(h,x,!1);return function(){e.removeEventListener(h,x,!1)}}:function(e,h){e.attachEvent("on"+h,x);return function(){e.detachEvent(h,x)}};p&&!x()&&(w=[B(l,"load"),B(p,"readystatechange"),B(l,"DOMContentLoaded")],h=setTimeout(D,t));define("curl/domReady",function(){function e(h){z?h():y.push(h)}e.then=e;e.amd=!0;return e})})(this,this.document);(function(l,p,v){define("curl/plugin/js",["curl/_privileged"],function(l){function D(e,w,h){function p(){r||(t<new Date?h():setTimeout(p,10))}var t,r,q;t=(new Date).valueOf()+(e.ga||3E5);h&&e.a&&setTimeout(p,10);q=l.core.s(e,function(){r=!0;e.a&&(e.C=v(e.a));!e.a||e.C?w(q):h()},function(e){r=!0;h(e)})}function C(e,l){D(e,function(){var h=y.shift();t=0<y.length;h&&C.apply(null,h);l.h(e.C||!0)},function(e){l.f(e)})}var A={},y=[],E=p&&!0==p.createElement("script").async,z,t,B=/\?|\.js\b/;z=l.Promise;return{dynamic:!0,normalize:function(e,l){var h=e.indexOf("!");return 0<=h?l(e.substr(0,h))+e.substr(h):l(e)},load:function(e,l,h,p){function v(e){(h.error||function(e){throw e;})(e)}var r,q,x,H,m;r=0<e.indexOf("!order");q=e.indexOf("!exports=");x=0<q?e.substr(q+9):p.a;H="prefetch"in p?p.prefetch:!0;e=r||0<q?e.substr(0,e.indexOf("!")):e;q=(q=p.dontAddFileExt||p.i)?RegExp(q):B;m=l.toUrl(e);q.test(m)||(m=m.lastIndexOf(".")<=m.lastIndexOf("/")?m+".js":m);m in A?A[m]instanceof z?A[m].m(h,v):h(A[m]):(e={name:e,url:m,fa:r,a:x,ga:p.timeout},A[m]=l=new z,l.m(function(e){A[m]=e;h(e)},v),r&&!E&&t?(y.push([e,l]),H&&(e.N="text/cache",D(e,function(e){e&&e.parentNode.removeChild(e)},function(){}),e.N="")):(t=t||r,C(e,l)))},cramPlugin:".."+"/"+"cram/js"}})})(this,this.document,function(l){try{return eval(l)}catch(p){}});define("curl/plugin/domReady",[".."+"/"+"domReady"],function(l){return{load:function(p,v,x){l(x)}}});}).call(this);[].slice.apply(document.querySelectorAll('figure.interactive[data-interactive]')).forEach(function(el){require([el.getAttribute('data-interactive')],function(interactive){interactive.boot(el,document,window.guardian.config);},function(err){console.log('Interactive failed',mainJS);console.log('Error:',err);});require(['ophan/ng'],function(ophan){var a=el.querySelector('a');var href=a&&a.href;if(href){ophan.trackComponentAttention(href,el);}});[].slice.apply(document.querySelectorAll('iframe.interactive-atom-fence')).forEach(function(el){var srcdoc;if(!el.srcdoc){srcdoc=el.getAttribute('srcdoc');el.contentWindow.contents=srcdoc;el.src='javascript:window["contents"]';}});});
const pillar='News';(function(){function convertContentType(contentType){var result=contentType;if(typeof contentType==='string'){result=contentType.toLowerCase().split(' ').join('');}return result;}function getQueryParam(key){var query=window.location.search.substring(1);var vars=query.split("&");var pairs=vars.map(function(x){return x.split('=')});return pairs.filter(function(xs){return xs.length==2&&xs[0]==key}).map(function(xs){return xs[1]})[0];}function getAnalyticsEdition(){var edition=(guardian.config.page.edition||'').toLowerCase()
return edition==='int'?'international':edition;}function getAnalyticsTitle(){var analyticsTitle=(guardian.config.page.webTitle||'');return(analyticsTitle==='Network Front')?getAnalyticsEdition()+' network front':analyticsTitle;}function getExperienceValue(){return'none';}var identityId=null;if(guardian.config.user){identityId=guardian.config.user.id;}var isLoggedIn=(!!identityId).toString();(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,'script','//www.google-analytics.com/analytics.js','ga');ga('create','UA-78705427-1','auto','allEditorialPropertyTracker',{'sampleRate':100,'siteSpeedSampleRate':0.1,'userId':identityId});ga('create','UA-33592456-1','auto','guardianTestPropertyTracker',{'sampleRate':5,'siteSpeedSampleRate':0.1,'userId':identityId});ga('allEditorialPropertyTracker.set','forceSSL',true);ga('allEditorialPropertyTracker.set','title',getAnalyticsTitle());ga('allEditorialPropertyTracker.set','anonymizeIp',true);ga('allEditorialPropertyTracker.set','dimension1',guardian.config.ophan.pageViewId);ga('allEditorialPropertyTracker.set','dimension2',guardian.config.ophan.browserId);ga('allEditorialPropertyTracker.set','dimension3','theguardian.com');ga('allEditorialPropertyTracker.set','dimension4',guardian.config.page.section);ga('allEditorialPropertyTracker.set','dimension5',convertContentType(guardian.config.page.contentType));ga('allEditorialPropertyTracker.set','dimension6',guardian.config.page.commissioningDesks);ga('allEditorialPropertyTracker.set','dimension7',guardian.config.page.contentId);ga('allEditorialPropertyTracker.set','dimension8',guardian.config.page.authorIds);ga('allEditorialPropertyTracker.set','dimension9',guardian.config.page.keywordIds);ga('allEditorialPropertyTracker.set','dimension10',guardian.config.page.toneIds);ga('allEditorialPropertyTracker.set','dimension11',guardian.config.page.seriesId);ga('allEditorialPropertyTracker.set','dimension15',identityId);ga('allEditorialPropertyTracker.set','dimension16',isLoggedIn);ga('allEditorialPropertyTracker.set','dimension21',getQueryParam('INTCMP'));ga('allEditorialPropertyTracker.set','dimension22',getQueryParam('CMP_BUNIT'));ga('allEditorialPropertyTracker.set','dimension23',getQueryParam('CMP_TU'));ga('allEditorialPropertyTracker.set','dimension26',(!!guardian.config.page.isHosted).toString());ga('allEditorialPropertyTracker.set','dimension27',navigator.userAgent);ga('allEditorialPropertyTracker.set','dimension29',window.location.href);ga('allEditorialPropertyTracker.set','dimension30',getAnalyticsEdition());ga('allEditorialPropertyTracker.set','dimension43',getExperienceValue());ga('allEditorialPropertyTracker.set','dimension50',pillar);if(document.location.hash==='#fbLogin'){ga('allEditorialPropertyTracker.set','referrer',null);document.location.hash='';}ga('guardianTestPropertyTracker.set','forceSSL',true);ga('guardianTestPropertyTracker.set','title',getAnalyticsTitle());ga('guardianTestPropertyTracker.set','anonymizeIp',true);ga('guardianTestPropertyTracker.set','dimension1',guardian.config.ophan.pageViewId);ga('guardianTestPropertyTracker.set','dimension2',guardian.config.ophan.browserId);ga('guardianTestPropertyTracker.set','dimension3','theguardian.com');ga('guardianTestPropertyTracker.set','dimension4',guardian.config.page.section);ga('guardianTestPropertyTracker.set','dimension5',convertContentType(guardian.config.page.contentType));ga('guardianTestPropertyTracker.set','dimension6',guardian.config.page.commissioningDesks);ga('guardianTestPropertyTracker.set','dimension7',guardian.config.page.contentId);ga('guardianTestPropertyTracker.set','dimension8',guardian.config.page.authorIds);ga('guardianTestPropertyTracker.set','dimension9',guardian.config.page.keywordIds);ga('guardianTestPropertyTracker.set','dimension10',guardian.config.page.toneIds);ga('guardianTestPropertyTracker.set','dimension11',guardian.config.page.seriesId);ga('guardianTestPropertyTracker.set','dimension15',identityId);ga('guardianTestPropertyTracker.set','dimension16',isLoggedIn);ga('guardianTestPropertyTracker.set','dimension21',getQueryParam('INTCMP'));ga('guardianTestPropertyTracker.set','dimension22',getQueryParam('CMP_BUNIT'));ga('guardianTestPropertyTracker.set','dimension23',getQueryParam('CMP_TU'));ga('guardianTestPropertyTracker.set','dimension26',(!!guardian.config.page.isHosted).toString());ga('guardianTestPropertyTracker.set','dimension27',navigator.userAgent);ga('guardianTestPropertyTracker.set','dimension29',window.location.href);ga('guardianTestPropertyTracker.set','dimension30',getAnalyticsEdition());ga('guardianTestPropertyTracker.set','dimension43',getExperienceValue());ga('guardianTestPropertyTracker.set','dimension50',pillar);if(document.location.hash==='#fbLogin'){ga('guardianTestPropertyTracker.set','referrer',null);document.location.hash='';}ga('allEditorialPropertyTracker.send','pageview',{hitCallback:function(){var image=new Image();image.src="//phar.gu-web.net/count/pvg.gif";}});try{var NG_STORAGE_KEY='gu.analytics.referrerVars';var referrerVarsData=window.sessionStorage.getItem(NG_STORAGE_KEY);var referrerVars=JSON.parse(referrerVarsData);if(referrerVars&&referrerVars.value){var d=new Date().getTime();if(d-referrerVars.value.time<60*1000){ga('allEditorialPropertyTracker.send','event','Click','Internal',referrerVars.value.tag,{nonInteraction:true,dimension12:referrerVars.value.path});}window.sessionStorage.removeItem(NG_STORAGE_KEY);}}catch(e){}guardian.app&&guardian.app.mediator&&guardian.app.mediator.emit('modules:ga:ready');})();
var _comscore=_comscore||[];_comscore.push({c1:"2",c2:"6035250",comscorekw:guardian.config.page.keywords});(function(){var s=document.createElement("script"),el=document.getElementsByTagName("script")[0];s.async=true;s.src="https://sb.scorecardresearch.com/beacon.js";el.parentNode.insertBefore(s,el);})();
!function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments);},s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js',a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script');twq('init','nyl43');twq('track','PageView');